

7 April 2026

INDEX	Up/Down	Percentage	Points	Index Closing
S&P BSE SENSEX	▲	0.69%	509.73	74616.58
NIFTY 50	▲	0.68%	155.40	23123.65
S&P BSE 500	▲	0.50%	165.12	33395.05

Index	Open	High	Low	Close	52 W High	52 W Low
SENSEX	73,734.36	74,686.32	73,282.41	74,616.58	86,159.02	71,425.01
NIFTY	22,838.70	23,153.85	22,719.30	23,123.65	26,373.20	22,182.55

SENSEX Gainers	20	NIFTY Gainers	35
SENSEX Losers	10	NIFTY Losers	15

Exchange	Advances	Declines	Advance/Decline Ratio	Unchanged
BSE	2475	1512	1.64	304
NSE	1385	869	1.59	17

Top 5 SENSEX Drivers				Top 5 Gainers & Losers (X – Sensex)			
Gainers	(%)	Losers	(%)	Gainers	(%)	Losers	(%)
HCL Technologies Ltd	2.77%	Interglobe Aviation Ltd	-0.87%	Accuracy Shipping Ltd	20.00%	Raj Television Network Lt	-19.99%
Tata Consultancy Services	2.68%	Adani Ports and Special E	-0.52%	Alkali Metals Limited	20.00%	Yug Decor Ltd	-19.94%
Infosys Ltd	2.60%	Mahindra And Mahindra Ltd	-0.50%	Alphageo (India) Ltd	20.00%	Sabrimala Industries Indi	-13.61%
Bharti Airtel Ltd	2.13%	Titan Company Ltd	-0.31%	Cybertech Systems and Sof	20.00%	Paragon Finance Ltd	-13.02%
Sun Pharmaceutical Indust	1.67%	Trent Ltd	-0.27%	KPT Industries Ltd	20.00%	Naapbooks Ltd	-11.63%
Top 5 NIFTY Drivers				Top 5 Gainers & Losers (X – Nifty)			
Gainers	(%)	Losers	(%)	Gainers	(%)	Losers	(%)
Wipro Ltd	3.71%	Dr Reddy's Laboratories L	-1.63%	Alkali Metals Limited	20.00%	Raj Television Network Lt	-19.97%
Hindalco Industries Ltd	2.97%	Interglobe Aviation Ltd	-1.01%	Alphageo (India) Ltd	20.00%	Jubilant FoodWorks Ltd	-10.49%
Tata Consultancy Services	2.81%	Adani Enterprises Ltd	-0.96%	Likhitha Infrastructure L	20.00%	Amir Chand Jagdish Kumar	-10.00%
HCL Technologies Ltd	2.65%	Apollo Hospitals Enterpri	-0.60%	Cybertech Systems and Sof	19.99%	Entero Healthcare Solutio	-6.74%
Infosys Ltd	2.59%	Trent Ltd	-0.49%	UMA Exports Ltd	19.98%	Pace Digitek Ltd	-6.42%

Note: - The above calculations are based on Closing Prices and not on Last Traded Prices.

**Alembic Pharma gained 6% on getting USFDA nod for Dapagliflozin tablets:**

Alembic Pharmaceuticals shares jumped 6% logging an intra-day high at ₹695.4 per share after receiving final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Dapagliflozin Tablets, 5 mg and 10 mg. Dapagliflozin Tablets is a generic version of AstraZeneca's Farxiga, which had an estimated US market size of \$10,487 million for the twelve months ending December 2025, according to IQVIA. Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used to reduce the risk of hospitalisation for heart failure in adults with type 2 diabetes mellitus who have either established cardiovascular disease or multiple cardiovascular risk factors. It is also indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Alembic was among the first ANDA applicants to submit a substantially complete application with a Paragraph IV certification for the drug. As a result, the company is eligible for 180 days of shared generic drug exclusivity.

Titagarh Rail Systems shares jumped 13.2% on approval from Ministry of Ports:

Shares of Titagarh Rail Systems saw strong buying interest after the company announced that its wholly owned subsidiary, Titagarh Naval Systems, has received in-principle approval from the Ministry of Ports, Shipping and Waterways for a project in West Bengal. Following the development, the stock surged up to 13.2% to hit an intraday high of ₹723.85 per share. The rally in the stock followed the company's announcement that Titagarh Naval Systems has received in-principle approval for its brownfield expansion project at Falta, West Bengal, under the Government of India's Shipbuilding Development Scheme (SbDS). The government has been promoting the domestic shipbuilding ecosystem through initiatives such as the Shipbuilding Financial Assistance Scheme (SBFAS) and the Shipbuilding Development Scheme (SbDS). These efforts, supported by recent Union Budget priorities, aim to strengthen India's shipbuilding capabilities, enhance infrastructure, and support both defence and commercial vessel construction, while improving global competitiveness.

Swan Defence hit 5% upper circuit on ₹1,500-3,000 crore bulk carrier order:

Swan Defence and Heavy Industries shares today hit the upper circuit of 5% at ₹1,703.45 in intraday as the company shared the details about a fresh order. Swan Defence shares have gained for three consecutive trading sessions. Today's buying in Swan Defence was buoyed by an announcement wherein the company secured India's first ammonia dual-fuel bulk carrier order. As per the filing, Swan Defence has secured an order from Energy ONE Limited for the construction of four 92,500 DWT dual-fuel ammonia bulk carriers, marking a first for the country. Swan Defence said that the order lies in category 4, which ranges between ₹1,500 to ₹3,000 crore. "These will be the first ammonia dual-fuel ships built in India and are also among the largest commercial vessels ever to be built at an Indian shipyard," Swan Defence said in filing. Measuring 229.5m in length with a beam of 37m, each of the dual-fuel vessels will be equipped with ammonia-fuelled propulsion system. The vessels will be designed by KMS-EMEC, South Korea and classed by Det Norske Veritas (DNV) – one of the leading Class societies in the world.

CreditAccess Grameen jumped 10.4% on strong Q4 update, asset quality recovery:

Shares of Indian microfinance company CreditAccess Grameen rallied around 10.4% to hit a high of ₹1,301.60 after the company said that it has concluded the fiscal year 2026 (FY26) on a strong note, showing robust business momentum and complete normalisation of asset quality. The microfinance lender's gross loan portfolio (GLP) stood at ₹29,590 crore in the March 2026 quarter (Q4FY26), up 14% from ₹25,948 crore in the year-ago quarter. In the December 2025 quarter (Q3FY26), the company reported GLP of ₹26,566 crore. Disbursements for the fourth quarter were at ₹8,313 crore, up 28% Y-o-Y, while total disbursements for FY26 increased 24% to ₹24,860 crore. The company's digital customer app, Mahi, added 840,000 users during the year. The share of retail finance increased to 18% in March 2026 from 6% in the year-ago period, driven by strong retention and the graduation of high-vintage, well-performing borrowers. The company's asset quality has fully normalised across all geographies, with overall X-Bucket collection efficiency (CE) at 99.84% in March 2026. It also added that 183 new branches were opened in FY26, including 18 during Q4.

Shyam Metalics up 7.8% on posting Q4 update; stainless steel sales up 59% YoY:

Shyam Metalics and Energy shares gained 7.8% logging an intra-day high at ₹856.2 per share after the company released its sales figures for March and Q4FY26. The company's stainless steel sales volume rose 58.91% year-on-year (Y-o-Y) in March to 10,519 MT, while average realisation increased 19.01% to ₹1,52,633 per MT. For the full year, stainless steel volumes grew 11.49%, while realisations rose 6.73%. In aluminium foil, March sales volume increased 8.51% Y-o-Y to 2,160 MT, with average realisation up 18.48% to ₹4,26,108 per MT. On a quarterly basis, aluminium foil volumes rose 5.27%, while realisations improved 7.81%. Pellet sales volume climbed 44.31% Y-o-Y in March to 1,06,917 MT, while realisation rose 10.92%. On a full-year basis, pellet volumes grew 39.90%, with realisations up 5.09%. In speciality alloys, March sales volume increased 8.64% Y-o-Y to 20,130 MT, while average realisation rose 12.88%. For FY26, speciality alloy volumes were up 11.88%, though realisations fell 2.15%. The company's carbon steel sales volume rose 3.09% Y-o-Y in March to 1,55,938 MT, while realisation increased 3.74%. Quarterly carbon steel volumes rose 10.47%, with realisations up 12.69%.

**Disclosures and Disclaimer**

Disclosures and Disclaimers: This Report is published by Sunidhi Securities & Finance Limited (hereinafter referred to as "Sunidhi") SEBI Research Analyst Registration Number: INH000001329 for private circulation. Sunidhi is a registered Stock Broker with National Stock Exchange of India Limited, BSE Limited and Metropolitan Stock Exchange of India Limited in cash, derivatives and currency derivatives segments. It is also having registration as a Depository Participant with CDSL.

Sunidhi has other business divisions with independent research teams separated by Chinese walls, and therefore may, at times, have different or contrary views on stocks and markets.

Sunidhi or its associates has not been debarred / suspended by SEBI or any other regulatory authority for accessing / dealing in securities Market. Sunidhi or analyst or his relatives do not hold any financial interest in the subject company. Associates may have such interest in its ordinary course of business as a distinct and independent body. Sunidhi or its associates or Analyst do not have any conflict or material conflict of interest at the time of publication of the research report with the company covered by Analyst.

Sunidhi or its associates / analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months. Sunidhi or its associates has not received any compensation or other benefits from the company covered by Analyst or third party in connection with the research report. Analyst has not served as an officer, director or employee of subject company and Sunidhi / analyst has not been engaged in market making activity of the subject company.

Analyst or his relatives do not hold beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report. Sunidhi or its associates may have investment positions in the stocks recommended in this report, which may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report. However, Sunidhi is maintaining Chinese wall between other business divisions or activities. Analyst has exercised due diligence in checking correctness of details and opinion expressed herein is unbiased.

This report is meant for personal informational purposes and is not be construed as a solicitation or financial advice or an offer to buy or sell any securities or related financial instruments. While utmost care has been taken in preparing this report, we claim no responsibility for its accuracy. Recipients should not regard the report as a substitute for the exercise of their own judgment. Any opinions expressed in this report are subject to change without any notice and this report is not under any obligation to update or keep current the information contained herein. Past performance is not necessarily indicative of future results. This report accepts no liability whatsoever for any loss or damage of any kind arising out of the use of all or any part of this report.

Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of the companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment.

The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true, but we do not represent that it is accurate or complete and it should not be relied on as such, as this document is for general guidance only. Sunidhi or any of its affiliates/ group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Sunidhi has not independently verified all the information contained within this document. Accordingly, we cannot testify, nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this document. While Sunidhi endeavors to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. Neither Sunidhi nor its directors, employees or affiliates shall be liable for any loss or damage that may arise from or in

connection with the use of this information.

Sunidhi Securities & Finance Ltd. – Research Analyst – INH000001329

Kalpataru Inspire, Unit.1, 8th floor, Opp. Grand Hyatt Hotel, Santacruz East, Mumbai-400055

Bombay Stock Exchange (BSE)	National Stock Exchange of India Ltd (NSE)	Metropolitan Stock Exchange of India Limited (MSEI)
Registration no. INZ000169235	Registration no. INZ000169235	Registration no. INZ000169235
Compliance Officer Name:	Mr. Mahesh Desai	Phone No: 9122-66771777